Approach to MPN Symptom Assessment Holly GeyerRuben A. Mesa Myeloproliferative Neoplasms (B Stein, Section Editor) 23 September 2017 Pages: 381 - 388
Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis Karlyn Martin Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 389 - 396
Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature Amy ZhouAmber AfzalStephen T. Oh Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 397 - 405
Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms Charles Elliott FoucarBrady Lee Stein Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 406 - 414
Chronic Myeloid Leukemia—the Promise of Tyrosine Kinase Inhibitor Discontinuation Ravi Kishore NarraKathryn E. FlynnEhab Atallah Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 415 - 423
Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender Jeffrey Patterson-FortinAlison R. Moliterno Myeloproliferative Neoplasms (B Stein, Section Editor) 25 September 2017 Pages: 424 - 431
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia Kim-Hien T. DaoJeffrey W. TynerJason Gotlib Myeloproliferative Neoplasms (B Stein, Section Editor) 06 October 2017 Pages: 432 - 441
Familial MPN Predisposition Tsewang TashiSabina SwierczekJosef T. Prchal Myeloproliferative Neoplasms (B Stein, Section Editor) 13 October 2017 Pages: 442 - 447
Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics Aaron C. ShaverAdam C. Seegmiller Myelodysplastic Syndromes (M Savona, Section Editor) 18 August 2017 Pages: 448 - 454
Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times Sagar S. PatelAaron T. Gerds Myelodysplastic Syndromes (M Savona, Section Editor) 18 August 2017 Pages: 455 - 460
Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS Aziz NazhaRafael Bejar Myelodysplastic Syndromes (M Savona, Section Editor) 26 August 2017 Pages: 461 - 467
Therapy for Chronic Myelomonocytic Leukemia in a New Era Tamara K. MoyoMichael R. Savona Myelodysplastic Syndromes (M Savona, Section Editor) 06 October 2017 Pages: 468 - 477
Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes Leylah M. DrusboskyChristopher R. Cogle Myelodysplastic Syndromes (M Savona, Section Editor) Open access 14 September 2017 Pages: 478 - 483
Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies Lorenzo Falchi CART and Immunotherapy (M Ruella, Section Editor) 18 August 2017 Pages: 484 - 494
Minimal Residual Disease Eradication in CML: Does It Really Matter? Srinivas K. TantravahiRaga S. GuthulaMichael W. Deininger Chronic Myeloid Leukemias (J Pinilla-Ibarz, Section Editor) 29 August 2017 Pages: 495 - 505